Cronos Group Inc.
HealthcareNASDAQ:CRON · NASDAQ Global Market
-$0.07 today
Vol 0.85M · Avg 1.52M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $824.6M |
| Receivables | $52.5M |
| Inventory | $48.8M |
| Other Current | $5.0M |
| Total Current Assets | $930.9M |
| PP&E (Net) | $143.9M |
| Goodwill | $65.7M |
| Intangible Assets | $8.6M |
| Long-term Investments | $26.1M |
| Tax Assets | $843.8K |
| Other Non-current | $1 |
| Total Non-current Assets | $245.0M |
| Total Assets | $1.2B |
Analysis
Selected assets total $1.2B for Latest. The largest visible component is Cash & Equivalents at $824.6M, about 70.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $791.8M -7.8% | $858.8M +28.3% | $669.3M -12.5% | $764.6M -13.8% | $887.0M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $40.0M | $0 -100.0% | $192.2M +70.0% | $113.1M -3.9% | $117.7M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $57.2M +92.1% | $29.8M -17.0% | $35.9M +14.6% | $31.3M -6.0% | $33.3M | $533.8M | $399.4M | -$1.7B |
| Inventory | $46.8M +41.0% | $33.1M +8.7% | $30.5M -18.8% | $37.6M +14.5% | $32.8M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $8.3M -42.0% | $14.4M +166.2% | $5.4M -23.9% | $7.1M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $944.1M +0.9% | $936.1M +0.3% | $933.3M -2.8% | $960.2M -11.1% | $1.1B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $147.3M +9.4% | $134.6M +121.3% | $60.8M -3.2% | $62.8M -24.3% | $83.0M | $1.2B | $1.5B | $687.8M |
| Goodwill | $66.5M +4.8% | $63.5M +5903.1% | $1.1M +2.3% | $1.0M -5.9% | $1.1M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $8.9M -20.1% | $11.1M -47.2% | $21.1M -21.1% | $26.7M +47.7% | $18.1M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $7.7M +172.4% | $2.8M -94.9% | $54.7M -39.0% | $89.7M -33.6% | $135.2M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $1.9M -26.6% | $2.6M +1037.6% | $226.0K | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $20.8M +34.3% | $15.5M -77.5% | $69.0M -4.8% | $72.5M -10.2% | $80.7M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $253.1M +10.0% | $230.1M +11.2% | $207.0M -18.2% | $252.9M -20.5% | $318.0M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $1.2B +2.6% | $1.2B +2.3% | $1.1B -6.0% | $1.2B -13.2% | $1.4B | $13.3B | $11.9B | $10.6B |
| Account Payables | $11.6M -31.4% | $17.0M +39.9% | $12.1M +8.7% | $11.2M +0.4% | $11.1M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $11.8M +0.7% | $11.8M -68.3% | $37.1M +932.2% | $3.6M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $20.1M +50170.0% | $40.0K -60.8% | $102.0K +580.0% | $15.0K -99.9% | $14.4M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $48.2M -3.0% | $49.7M +20.1% | $41.4M -39.2% | $68.1M +25.3% | $54.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $4.1M +14.7% | $3.6M +1869.1% | $181.0K | $0 -100.0% | $81.0K | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $733.0K -31.7% | $1.1M +7.0% | $1.0M -27.5% | $1.4M -27.7% | $1.9M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $6.0M +6.5% | $5.6M +105.2% | $2.7M -30.2% | $3.9M -56.8% | $9.1M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $54.2M -2.1% | $55.3M +25.3% | $44.1M -38.7% | $72.0M +13.5% | $63.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $661.8M -1.2% | $669.9M +1.2% | $662.2M +8.3% | $611.3M +2.7% | $595.5M | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $447.8M -2.2% | $457.7M +9.8% | $416.7M -15.1% | $490.7M -25.6% | $659.4M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$16.8M +73.5% | -$63.5M -407.2% | $20.7M +2694.5% | -$797.0K -101.6% | $49.9M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 +100.0% | -$48.4M | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $49.1M +4.6% | $46.9M +1461.2% | -$3.4M -18.0% | -$2.9M +1.6% | -$3.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $1.1B +2.9% | $1.1B +1.4% | $1.1B -3.9% | $1.1B -14.5% | $1.3B | $9.1B | $7.7B | $3.3B |
| Total Debt | $1.5M -25.2% | $2.0M -21.0% | $2.6M -34.1% | $3.9M -60.5% | $9.8M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$790.3M +7.8% | -$856.8M -28.5% | -$666.7M +12.4% | -$760.8M +13.3% | -$877.2M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
$1.40B
IRadimed Corporation
NASDAQ:IRMD
$1.20B
Collegium Pharmaceutical, Inc.
NASDAQ:COLL
$1.12B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Pacira BioSciences, Inc.
NASDAQ:PCRX
$904.31M
Amphastar Pharmaceuticals, Inc.
NASDAQ:AMPH
$885.83M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Embecta Corp.
NASDAQ:EMBC
$183.92M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does CRON have?
Cronos Group Inc. (CRON) reported $791.79M in cash and equivalents in fiscal 2025.
How much debt does CRON carry?
Cronos Group Inc. (CRON) reported $1.51M of total debt, with net debt of -$790,285,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.